

# NIH Public Access

**Author Manuscript** 

*Cornea*. Author manuscript; available in PMC 2011 June 28.

Published in final edited form as:

Cornea. 2009 October ; 28(9): 981–985. doi:10.1097/ICO.0b013e3181a0a3e6.

## Donor Risk Factors for Graft Failure in the Cornea Donor Study

Joel Sugar, MD<sup>1</sup>, Monty Montoya, MBA<sup>2</sup>, Mariya Dontchev, MPH<sup>3</sup>, Jean Paul Tanner, MPH<sup>3</sup>, Roy Beck, MD, PhD<sup>3</sup>, Robin Gal, MSPH<sup>3</sup>, Shawn Gallagher, PhD<sup>4</sup>, Ronald Gaster, MD<sup>5</sup>, Ellen Heck, MS, MA<sup>6</sup>, Edward J. Holland, MD<sup>7</sup>, Craig Kollman, PhD<sup>3</sup>, Jackie Malling<sup>8</sup>, Mark J. Mannis, MD<sup>9</sup>, Jason Woody<sup>10</sup>, and for the Cornea Donor Study Investigator Group <sup>1</sup>University of Illinois at Chicago, Chicago, IL

<sup>2</sup>SightLife, Seattle, WA

<sup>3</sup>Jaeb Center for Health Research, Tampa, FL

<sup>4</sup>Eye Doctors of Lancaster, Lancaster, PA

<sup>5</sup>University of California Irvine, Irvine, CA

<sup>6</sup>Transplant Services Center UT Southwestern, Dallas, TX

<sup>7</sup>Cincinnati Eye Institute, Cincinnati, OH

<sup>8</sup>Minnesota Lions Eye Bank, Minneapolis, MN

<sup>9</sup>University of California Davis, Sacramento, CA

<sup>10</sup>Central Florida Lions Eye & Tissue Bank, Inc, Tampa, FL

## Abstract

**Purpose**—To assess the relationship between donor factors and 5-year corneal graft survival in the Cornea Donor Study (CDS).

**Methods**—Donor corneas met criteria established by the Eye Bank Association of America, had an endothelial cell density of 2300–3300/mm<sup>2</sup>, and were determined to be of good to excellent quality by the eye banks. Donor corneas were assigned using a random approach and surgeons were masked to information about the donor cornea including donor age. Surgery and post-operative care were performed according to the surgeons' usual routines and subjects were followed for five years. Donor and donor cornea factors were evaluated for their association with graft failure, which was defined as a regraft or a cloudy cornea that was sufficiently opaque to compromise vision for a minimum of three consecutive months.

**Results**—Graft failure was not significantly associated with the type of tissue retrieval (enucleation versus in situ), processing factors, timing of use of the cornea, or to characteristics of the donor or the donor cornea. Adjusting for donor age did not affect the results.

**Conclusion**—Donor and donor cornea characteristics do not impact graft survival rates for corneas comparable in quality to those used in this study.

Conflict of Interest: None

**Corresponding Author:** Joel Sugar, M.D. c/o Jaeb Center for Health Research, 15310 Amberly Drive, Suite 350, Tampa, FL 33647, Phone: (813) 975-8690; Fax: (813) 975-8761; cds@jaeb.org.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

#### Keywords

cornea transplant; graft failure; cornea donor

## INTRODUCTION

The Cornea Donor Study (CDS) recently published results demonstrating no difference in corneal graft survival at 5 years related to donor age.<sup>1</sup> Although eye banks routinely gather information on both the donor and the quality of the corneal tissue prior to distributing tissue for transplantation, relatively little information is present in the literature concerning the impact of these factors on graft survival.<sup>2</sup> In the CDS, information on cornea donors, tissue handling, and tissue findings was obtained and assessed in order to examine any potential impact on graft survival at 5 years. The results of these analyses are presented here.

## MATERIALS AND METHODS

#### **Study Protocol**

Details of the CDS protocol have been reported previously<sup>1, 3, 4</sup> and the key aspects are briefly summarized. The study protocol was approved by institutional review boards for each eye bank and at each investigational site.

Eligible subjects were between 40 and 80 years old and had corneal disease associated with endothelial dysfunction and moderate risk of failure (principally Fuchs' dystrophy and pseudophakic corneal edema). Written informed consent was obtained from each subject. Eligible donor corneas met Eye Bank Association of America (EBAA) standards for human corneal transplantation.<sup>5, 6</sup> Eligibility criteria for the donor corneas assigned in the study are listed in Table 1. Eye banks obtained information about the cornea donor, including age, gender, race, history of diabetes and cause of death from medical records, health care provider interviews, and family members. Type of tissue recovery, either as whole eye (enucleation) or corneo-scleral rim removal (in situ), time from death to placement in preservative medium, body refrigeration time, and death to surgery time were recorded. Specific characteristics of the donor tissue were recorded, including epithelial slit lamp findings, stromal edema, arcus, folds in Descemet's membrane, the presence of "snail tracks" (linear ruptures of endothelial cells), and endothelial morphology by specular microscopy.

Clinical investigators and subjects were masked to all characteristics of the donor cornea, including age and endothelial cell density. Preoperative management, surgical technique, and postoperative care (including prescription of medications), were provided according to each investigator's customary routine. The visit schedule during the first 6 post-operative months was at the discretion of the investigator. Thereafter, the minimum follow-up visit schedule included a visit between six and 12 months and then annual visits through 5 years. Because of the trial's simple design, data collection at each visit was limited and included an assessment of graft clarity, signs of graft rejection, and intraocular pressure. The definition of graft failure, based on the definition used in the Collaborative Corneal Transplantation Studies (CCTS)<sup>7, 8</sup>, was a regraft or, in the absence of regraft, a cloudy cornea in which there was loss of central graft clarity sufficient to compromise vision for a minimum of three consecutive months. Further details of the classification scheme for graft failures has been published.<sup>1</sup>

#### **Statistical Methods**

The analysis included the 1,090 eligible subjects in the CDS. Baseline endothelial cell density was evaluated by the Reading Center for 658 cases. Donor race/ethnicity was excluded from the analysis due to the small number of subjects per group (41 African Americans, 11 Hispanics, 3 Asians, and 11 other).

Cumulative probabilities of graft failure (subsequently referred to as "graft failure rates") were calculated using the Kaplan–Meier method. Univariate Cox proportional hazards regression models were used to individually assess the association of each donor factor with graft failure. No significant deviations from the proportional hazards assumptions were detected. All reported p-values are two-sided. Because of multiple comparisons, *P* values  $\geq$  0.01 were not considered statistically significant. Statistical analyses were conducted using SAS version 9.1 software (SAS Institute Inc., Cary, NC).

## RESULTS

The donor characteristics and slit-lamp characteristics of the corneas have been reported in detail previously.<sup>3</sup> The distribution of each characteristic is indicated in Table 2.

Among the 135 eyes with graft failures, 102 (76%) had a regraft and 33 (24%) met the cloudy cornea failure criteria defined for the study without a regraft (30 had a cloudy cornea for at least three months and 3 had a cloudy cornea for less than three months without additional available follow up). Three graft failures were due to primary donor failure, 8 to uncorrectable refractive error, 48 to graft rejection, 46 to endothelial decompensation, and 30 to other causes.

As shown in Table 2, graft failure rates were not significantly impacted by any donor characteristics (gender, history of diabetes, or cause of death), by any factors related to the type of tissue retrieval, processing, timing of use of the cornea (time from death to preservation or time from death to surgery), or by any characteristics of the donor cornea (presence of endothelial polymorphism, endothelial cell damage, Descemet folds, snail tracks, baseline ECD, epithelial defects, epithelial haze, epithelial exposure, stromal edema, or arcus). Adjusting for donor age did not affect the results (data not shown). When analyses were conducted separately for rejection and non-rejection graft failures, no baseline donor factors were found to be associated with the rate of graft failure, based upon our prespecified level of significance (data not shown).

### DISCUSSION

While a number of factors evaluated here have been assessed in other studies, this prospective study is one of the few to address their impact on graft survival. The limitation of this study is that the tissue selection criteria excluded extremes such as prolonged death to preservation time and death to surgery time. Only mild to moderate epithelial, stromal, Descemet and endothelial variations were accepted. Nonetheless, the information obtained is useful in demonstrating the lack of any adverse impact of the abnormalities found in the ranges studied.

Data on donor cause of death and presence or absence of diabetes mellitus show no impact on five-year graft outcomes. Earlier studies have shown a similar lack of impact of donor cause of death on five-year graft survival.<sup>2</sup> Recently, deaths due to cancer have been implicated in post-operative endophthalmitis<sup>9</sup> but there were no cases of endophthalmitis attributable to the donor cornea in the CDS. Additional studies have shown no reason to exclude donors with cancer<sup>10</sup> but these did not look at graft survival. Graft outcome did not differ by method of tissue procurement (enucleation vs. *in situ* retrieval). Rootman and co-investigators reported no difference in initial donor tissue quality rating by procurement methodology but they did not look at graft outcomes beyond primary graft failure.<sup>11</sup> A recent study showed no difference in graft clarity at 3 months with either procurement method.<sup>12</sup>

Timing of tissue procurement, refrigeration, and use has been studied in the past and has also been shown, within limited ranges, to have no effect on graft outcome<sup>2</sup> although prolonged storage times, not studied here, may well have a deleterious effect<sup>13</sup>. Endothelial characteristics likewise had no impact on graft outcomes using the donor criteria of the CDS.<sup>14</sup>

Epithelial and stromal changes were generally mild with only one case of severe epithelial exposure and one with moderate stromal edema. While over half of the donor corneas had epithelial defects, these all involved less than 50% of the epithelium and had no statistically significant effect. Because of the relatively low prevalence of endothelial trauma related to tissue preparation, as manifested by snail tracks in the central cornea and present in only 7% of donor corneas, the impact of this type of trauma cannot be fully assessed.

While study of more extreme alterations of tissue would be of benefit, this study demonstrates effectively, as have the other reports from the CDS, that all tissue meeting the donor criteria used performs equally well. Continued follow-up of this cohort through 10 years is ongoing in order to assess any potential differences in longer-term survival.

#### Acknowledgments

**Funding/Support:** Supported by cooperative agreements with the National Eye Institute, National Institutes of Health, Department of Health and Human Services EY12728 and EY12358. Additional support provided by: Eye Bank Association of America, Bausch & Lomb, Inc., Tissue Banks International, Vision Share, Inc., San Diego Eye Bank, The Cornea Society, Katena Products, Inc., ViroMed Laboratories, Inc., Midwest Eye-Banks (Michigan Eye-Bank, Illinois Eye-Bank), Konan Medical Corp., Eye Bank for Sight Restoration, SightLife, Sight Society of Northeastern New York (Lions Eye Bank of Albany), Lions Eye Bank of Oregon

#### References

- Cornea Donor Study Investigator Group. The effect of donor age on corneal transplantation outcome: results of the cornea donor study. Ophthalmology. 2008; 115:620–626. [PubMed: 18387407]
- 2. Williams, KA.; Lowe, MT.; Bartlett, CM., et al. The Australian Corneal Graft Registry, 2007 report. Flinders University Press; 2007.
- Cornea Donor Study Group. Baseline donor characteristics in the Cornea Donor Study. Cornea. 2005; 24:389–396. [PubMed: 15829793]
- 4. Cornea Donor Study Group. Clinical profile and early surgical complications in the Cornea Donor Study. Cornea. 2006; 25:164–170. [PubMed: 16371775]
- 5. EBAA. Washington, DC: 2000. Eye Bank Association of America. Medical Standards.
- 6. Eye Bank Association of America. Medical Standards. 2006
- Collaborative Corneal Transplantation Studies Research Group. The Collaborative Corneal Transplantation Studies (CCTS): effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol. 1992; 110:1392–1403. [PubMed: 1417537]
- Collaborative Corneal Transplantation Studies Research Group. Design and methods of the Collaborative Corneal Transplantation Studies. Cornea. 1993; 12:93–103. [PubMed: 8500329]
- Hassan SS, Wilhelmus KR, Dahl P, et al. Infectious disease risk factors of corneal graft donors. Arch Ophthalmol. 2008; 126:235–239. [PubMed: 18268215]
- Wagoner MD, Dohlman CH, Albert DM, et al. Corneal donor material selection. Ophthalmology. 1981; 88:139–145. [PubMed: 7015217]

Cornea. Author manuscript; available in PMC 2011 June 28.

- Rootman DB, Wankiewicz E, Sharpen L, Baxter SA. In situ versus whole-globe harvesting of corneal tissue from remote donor sites: effects on initial tissue quality. Cornea. 2007; 26:270–273. [PubMed: 17413951]
- Jhanji V, Tandon R, Sharma N, et al. Whole globe enucleation versus in situ excision for donor corneal retrieval - a prospective comparative study. Cornea 2008;27(10):1103-8Sharma N, et al. Whole globe enucleation versus in situ excision for donor corneal retrieval - a prospective comparative study. Cornea. 2008; 27(10):1103–1108. [PubMed: 19034121]
- Wilhelmus KR, Stulting RD, Sugar J, Khan MM. Primary cornea graft failure: a national reporting system. Medical Advisory Board of the Eye Bank Association of America. Arch Ophthalmol. 1995; 113:1497–1502. [PubMed: 7487615]
- Cornea Donor Study Investigator Group. Donor age and corneal endothelial cell loss five years after successful cornea transplantation: specular microscopy ancillary study results. Ophthalmology. 2008; 115:627–632. [PubMed: 18387408]

## APPENDIX

A listing of the Cornea Donor Study Investigator Group, including clinical site investigators, eye bank staff, coordinating center staff, specular microscopy reading center staff, and committees, has been previously published online.<sup>1</sup>

The following CDS Publications Committee members independently reviewed and approved this manuscript for submission: John Affeldt, MD, Michael W. Belin, MD, Terry E. Burris, MD, Richard Eifermann, MD, Jonathan Macy, MD

Page 6

#### Table 1

## Cornea Donor Study Donor Tissue Eligibility Criteria

Age of do	nor at time of death: 10–75 years
Death to j	<b>preservation time:</b> $\leq 12$ hrs if body refrigerated or eyes iced and $\leq 8$ hrs if not
Death to s	surgery time: ≤5 days
Donor me	edical exclusions including cause of death: meets EBAA standards
Donor oc	ular exclusions: meets EBAA standards for excluding tissue plus no prior intraocular surgery (must be phakic)
Specular	microscopy:
•	Endothelial cell density 2300 to 3300 cells/mm <sup>2</sup>
•	Polymorphism/Polymegethism – none to no more than mild (slight)
•	Guttae – no true guttae
•	No evidence of central endothelial cell damage/trauma or dystrophy
Slit lamp Epitheliun	examination criteria: <u>n</u>
•	Defects of 50% or less of epithelium
•	Haze none to no more than moderate
•	Exposure – none to no more than moderate
Stroma	
•	Edema – none to no more than mild
•	Arcus – $\geq$ 8.0mm clear zone
Descemet	<u>'s membrane</u>
•	Folds – none to no more than few (mild)
Endotheliu	<u>um</u>
•	Snail tracks (endothelial stress lines) - none to no more than mild centrally
•	Guttae – no true guttae
•	No evidence of central endothelial cell damage/trauma or dystrophy
L	

#### Table 2

Baseline Donor Factors Predictive of Graft Failure (N=1,090)

		5-yr Graft		Hazard Ratio (99% confidence interva			rval) <sup>b</sup>
		Failure ±	0	0.5	1.0	2.0	3.
Donor Factors	Ν	99% CI <sup>a</sup>	Ľ				
Overall	1,090	$14\%\pm3\%$		1		1	
DONOR CHARACTERISTICS							
Gender							
Male	716	$13\%\pm3\%$					
Female	374	$15\% \pm 5\%$					
History of Diabetes							
No	891	$14\% \pm 3\%$					
Yes	199	$12\% \pm 6\%$			-•	_	
Cause of Death							
Cardio/Stroke	659	$14\% \pm 4\%$					
Cancer	207	$18\% \pm 7\%$			_ <b>_</b>		
Trauma	96	$11\% \pm 9\%$			•		
Respiratory	78	$11\% \pm 9\%$			•		
Other <sup>c</sup>	50	$9\%\pm12\%$			•		
RETRIEVAL AND TIMING							
FACTORS							
Type of Tissue Retrieval							
Enucleation	218	$13\% \pm 6\%$					
In situ	872	$13\% \pm 3\%$ $14\% \pm 3\%$		_			
Time from Death to Preservation		14/0 ± 5/0			•		
0-4 hrs	206	$17\% \pm 7\%$					
>4-8 hrs	200 577	$17/6 \pm 7/6$ $13\% \pm 4\%$					
>8 - 10 hrs	165	$13\% \pm 7\%$ $12\% \pm 7\%$					
>10 hrs	142	$12\% \pm 7\%$ $18\% \pm 9\%$		•			
Body Refrigerated	142	18/0 ± 9/0					
No	255	$15\% \pm 6\%$					
Yes	835	$13\% \pm 3\%$					
Time from Death to Preservation		$13/0 \pm 3/0$			•		
by Refrigeration	1						
Refrigerated $0 - 4$ hrs	107	$16\% \pm 10\%$					
Refrigerated $>4 - 8$ hrs	433	$10\% \pm 10\%$ $12\% \pm 4\%$				-	
Refrigerated $>8$ hrs	433 295	$12\% \pm 4\%$ $15\% \pm 6\%$					
Not Refrigerated $0-4$ hrs	293 99	$13\% \pm 0\%$ $17\% \pm 10\%$					
Not Refrigerated $>4$ hrs	156	$17\% \pm 10\%$ $14\% \pm 8\%$					
Time from Death to Surgery	150	$1470 \pm 070$			-		
0 - <3 days	146	$16\% \pm 8\%$					
3 - <4 days	146 597	$10\% \pm 8\%$ $14\% \pm 4\%$					
					-		
4-8 days <sup>d</sup>	347	$12\% \pm 5\%$			•		

None

was eight days)

Mild/ Moderate

 $^{a}$ CI = confidence interval

Snail Tracks – Peripheral

Mild/ Moderate/ Severe

1adrenal insufficiency, 1electrocution

		5-yr Graft	Hazard Ratio (99% confidence interval) <sup>b</sup>				
			0	0.5 1.0		2.0	
Donor Factors	Ν	99% CI <sup>a</sup>	Ŭ				3.
			1	1		I	1
DONOR CORNEA							
CHARACTERISTICS							
Baseline Endothelial Cell							
Density <sup>e</sup>	210	1 40 / 1 50 /					
2300 - <2500	318	$14\% \pm 5\%$					
2500 - <2700	270	$17\% \pm 6\%$		-	•		
2700 - <3000	361	$13\% \pm 5\%$			•	_	
≥3000	141	$9\% \pm 7\%$		•		-	
Polymorphism/Polymegethism	0.51	120/ 1 20/					
None	951	$13\% \pm 3\%$					
Mild(slight)/ Moderate <sup>t</sup>	139	$16\% \pm 9\%$		_			
Endothelial Cell Damage –							
Diffuse							
None	1054	$14\% \pm 3\%$					
Mild/ Moderate	36	$9\%\pm13\%$		•			
Endothelial Cell Damage –							
Peripheral							
None	1038	$14\%\pm 3\%$					
Mild	52	$8\%\pm10\%$	_	•			
Epithelium – Defects							
Clear and Intact	525	$12\% \pm 4\%$					
Defects on <50% of Epithelium	565	$15\% \pm 4\%$					
Epithelium – Haze							
None	733	$12\% \pm 3\%$					
Mild	315	$16\%\pm6\%$					
Moderate/ Severe <sup>g</sup>	42	$19\%\pm17\%$				•	
Epithelium – Exposure							
None	209	$12\% \pm 6\%$					
Mild	661	$16\% \pm 4\%$			<b>●</b> _		
Moderate/ Severe <sup>g</sup>	220	$10\% \pm 5\%$			•		
Stroma – Edema							
None	817	$14\% \pm 3\%$					
Mild/ Moderate <sup>f</sup>	273	$14\% \pm 5\%$ $14\% \pm 6\%$		_			
	215	17/0 - 0/0			-		
Arcus Present	200	170/ + 50/					
None	380	$17\% \pm 5\%$					
Present	710	$12\% \pm 3\%$					
Descemet Folds	276	120/					
None	376	$13\% \pm 5\%$					
Few (Mild)/ Moderate	714	$14\% \pm 4\%$		-	•		
Snail Tracks – Central	1011	120/ . 20/					
None	1011	$13\% \pm 3\%$					
Mild/ Moderate	79	$19\% \pm 12\%$		_			
Snail Tracks – Diffuse		120/ . 20/					
None	903	$13\% \pm 3\%$					

**NIH-PA** Author Manuscript

Page 8

Cornea. Author manuscript; available in PMC 2011 June 28.

b  $\circ$  signifies an upper 99% confidence limit > 3.00 (for moderate/severe epithelium – haze group the upper 99% confidence limit = 4.03)

<sup>c</sup>12 anoxia/asphyxiation, 10 renal, 6 hepatic, 4 neurological, 4 drug overdose, 3 gastrointestinal, 3 shock, 2 pancreatitis, 2 seizure, 2 undetermined,

 $^{d}$ Includes 17 subjects who received corneas where time from death to transplant longer than five days (15 were six days, 1 was seven days and 1

 $17\%\pm8\%$ 

 $15\%\pm 3\%$ 

 $8\%\pm5\%$ 

187

880

210

Sugar et al.

 $e_{658}^{e}$  values from the reading center and 432 from the eye bank. Results were similar when excluding the cases without a Reading Center value (data not shown).

 $f_{\rm Only\ one\ subject\ classified\ as\ moderate}$ 

<sup>g</sup>Only one subject classified as severe

**NIH-PA** Author Manuscript

Cornea. Author manuscript; available in PMC 2011 June 28.